Bristol-Myers Squibb Aktie News

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Prices €5 Billion of Senior Unsecured Notes.

Bristol Myers Squibb reached a $239 million settlement of claims that former Celgene shareholders were defrauded about prospects for the psoriasis drug Otezla, and multiple sclerosis treatment now known as Zeposia.

PHILADELPHIA & SAN FRANCISCO--(BUSINESS WIRE)--Dispatch Bio, a biotech company engineering a universal treatment across solid tumors leveraging its first-in-class Flare platform, today announced a clinical supply and collaboration agreement with Bristol Myers Squibb (“BMS”) to support the development of Dispatch's DISP-10 program. Under the agreement, BMS will provide idecabtagene vicleucel (id...

Bristol-Myers Squibb is a compelling value and income opportunity, trading near 52-week lows with a 5.4% dividend yield and low forward P/E. BMY's growth portfolio, led by Opdivo, Reblozyl, and Breyanzi, is offsetting legacy drug declines, supported by strong Q3 results and robust pipeline catalysts. Disciplined cost management, an A credit rating, and ample free cash flow reinforce BMY's profi...

Bristol-Myers Squibb (BMY) remains a "Strong Buy" rating, driven by robust growth in its hematology and cardiovascular portfolios, especially Breyanzi and Camzyos. Breyanzi and Reblozyl achieved impressive year-over-year revenue growth, each generating over >$1 billion and >$2 billion in annual sales, respectively. The $1.5 billion acquisition of Orbital Therapeutics positions BMY to advance in...

The volatile sector is seeing greater stability, and these four stocks can profit.

PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Showcases New Long-Term and Real-World Data From Cardiovascular Portfolio at the American Heart Association Scientific Sessions.

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Cash Tender Offers to Purchase Certain Notes.